Prediction: 2 ASX shares I think could soar 1,000% in the next 10 years

Tech and infant formula could achieve strong growth in the coming years.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Airtasker is growing its task platform rapidly in the US and UK, two huge markets
  • Bubs is growing its infant formula sales in both China and the US
  • While it's impossible to know the future, I think both of these businesses could achieve big things

There are a number of ASX shares that have achieved very strong returns over the past decade. It's hard to decide which names could go on to become large winners.

Some businesses have managed to achieve big things by becoming leading players, such as Altium Limited (ASX: ALU), Pro Medicus Ltd (ASX: PME), Pilbara Minerals Ltd (ASX: PLS) and Australian Ethical Investment Ltd (ASX: AEF).

If I had a crystal ball, it would probably tell me that there aren't going to be many ASX shares that go on to produce returns of 1,000% over the next decade. However, if I had to pick two that already have market caps of more than $100 million, I'd go for these two.

Kid on a skateboard with cardboard wings soars along the road.

Image source: Getty Images

Airtasker Ltd (ASX: ART)

Airtasker currently has a market capitalisation of $148 million according to the ASX. This business describes itself as "Australia's leading online marketplace for local services, connecting people and businesses who need work done with people who want to work".

The business is growing at a strong pace in my opinion. In the first quarter of FY23, the Airtasker platform saw 36% revenue growth to $8 million. Including the acquired Oneflare marketplace revenue, it saw total revenue growth of 80% to $10.5 million.

A key part of the plan is the ASX share's international growth. Australia is a great country, but the United Kingdom and United States represent very large addressable markets. In the first quarter of FY23, UK gross marketplace volume (GMV) jumped 68% year over year to £4.2 million annualised. While US posted tasks increased 4.7x year over year to 13,000.

I think there is a huge opportunity if Airtasker can keep growing in the US and UK at a compound annual growth rate (CAGR) of 30% over the next decade. Markets like Canada and South Africa would be natural markets to extend into.

The business has a gross profit margin of more than 90%, so new revenue is very profitable for Airtasker. It can invest heavily for growth in the coming years thanks to that strong profit margin, hopefully enabling a strong return. An increase in average task price can also help grow revenue, so it's an interesting idea in an inflationary environment.

With the Airtasker share price down 60% in 2022, I think it's at a great value starting point to grow from here.

Bubs Australia Ltd (ASX: BUB)

Bubs is a nutrition business that offers a number of products including A2 beta-casein protein infant formula, organic grass-fed infant formula, goat milk infant formula, organic baby food and more.

This business is also growing revenue at an impressive rate. In the first quarter of FY23, it saw group gross revenue growth of 28% to $23.6 million. Infant formula gross revenue went up 109% year over year.

The ASX share is seeing its market share increase in Australian retail, and its growing infant formula sales come with an attractive gross profit margin.

Bubs is building retail partnerships with a number of e-commerce players, including Amazon.com which just invited Bubs to be a "direct retailer under first-party (1P) relationship".

Chinese daigou revenue is growing at a double-digit pace and this bodes well for ongoing penetration in that huge market.

In the US, it has managed to achieve a total market share of 0.4%, or 9%, of the organic/health formula category in its first 13 weeks of operations. That's as it tries to help address the formula shortage in that country.

I'm not expecting Bubs to become a giant business. But, with a starting market cap of $224 million, it just needs to steadily grow its geographic reach to do well, in my opinion.

The Bubs share price has fallen 54% since mid-August. Just getting back to that level would represent a rise of more than 100%.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Airtasker. The Motley Fool Australia has recommended Bubs Australia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Small Cap Shares

Two health workers taking a break.
Small Cap Shares

Down 26% year to date, is it time to buy low on this ASX small-cap?

This exciting ASX small-cap is one to watch.

Read more »

Miner and company person analysing results of a mining company.
Small Cap Shares

This must-watch small cap is up 50% YTD – can it continue?

This small-cap has been rocketing higher in 2026.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Small Cap Shares

Morgans gives its verdict on these small-cap ASX shares

Let's see if the broker is bullish on these shares that are flying under the radar.

Read more »

A railway worker walks along the train tracks in a visi vest and speaking into a walkie talkie.
Small Cap Shares

While the market worried about war and AI, these 2 ASX small caps kept climbing

Big returns do not always come from the loudest stories on the ASX.

Read more »

Children skipping and jumping up a hill.
Small Cap Shares

2 ASX small-cap stocks tipped to double in the next year

These companies could rise as much as 166%.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Small Cap Shares

2 ASX shares that could rise 100% according to Bell Potter

These high-risk, high-reward shares are being recommended by the broker.

Read more »

A man raises his reading glasses in a look of surprise.
Small Cap Shares

Morgans just slapped a buy rating on this small-cap ASX share

Let's see what the broker is saying about this one.

Read more »